Navigation Links
The New England Journal of Medicine Publishes Results of Fidaxomicin Phase 3 Trial Showing Significantly Lower Recurrence Rates and Improved Global Cure Rates Compared to Vancomycin in Patients with Clostridium difficile Infection (CDI)
Date:2/2/2011

SAN DIEGO, Feb. 2, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced The New England Journal of Medicine has published results from the North American Phase 3 trial evaluating the safety and efficacy of the Company's novel antibiotic fidaxomicin as a treatment for patients with Clostridium difficile infection (CDI). The Phase 3 trial showed that fidaxomicin significantly reduced recurrence rates and increased global cure rates when compared to vancomycin, the only treatment approved by the U.S. Food and Drug Administration for CDI. The article titled, "Fidaxomicin versus Vancomycin for Clostridium difficile Infection," appears in the February 3, 2011 issue of The New England Journal of Medicine.

A multi-media news release containing video is available at the following link:  http://multivu.prnewswire.com/mnr/optimerpharma/47526/

"C. difficile has surpassed MRSA as a source for hospital acquired infection, and is associated with severe illness and death. More alarming, 20-30% of patients treated with current antibiotics will relapse," said Sherwood L. Gorbach, M.D., co-author and Optimer's Chief Medical Officer. "Data published in The New England Journal of Medicine shows that fidaxomicin not only maintained the high cure rate expected of vancomycin, but also demonstrated a 45% reduction in recurrences. Reduction in the rate of recurrence is a critical advancement for one of the most problematic aspects of CDI.  Fidaxomicin may represent a significant advance for physicians and hospitals to provide an effective treatment for patients with CDI.  At a time when our population is aging --the first of the baby boomers turned 65 in January – we welcome this innovation to treat CDI, in which the elderl
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. New England Biolabs Develops Novel Small RNA NGS Protocol: Reagents Improve Yield and Decrease Adaptor-Dimer Formation
2. CSL Behring Awards Advocacy Grants to Patient Groups in Maryland, New England, the Midwest and Washington
3. Canadas Michael Smith Genome Sciences Center Validates NEBNext™ DNA Sample Preparation Reagents From New England Biolabs for Use in Next Generation Sequencing
4. New England Journal of Medicine Publishes Data from Pivotal Phase 3 PROVENGE IMPACT Study
5. New England Biolabs Launches NEBNext(TM) DNA Sample Prep Master Mix Set 3 for Use with SOLiD(TM) 3
6. Wellcome Trust Sanger Institute to use NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for Next Generation Sequencing
7. Organogenesis CEO Geoff MacKay and COO / CFO Gary Gillheeney Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Winners in New England
8. Ontario Institute for Cancer Research Validates NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for use in Next Generation Sequencing
9. First U.K. Stem Cell Awareness Rally to Take Place in Manchester, England on August 9th, 2009
10. Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax(TM)) for the Treatment of Inhalation Anthrax
11. New England Journal of Medicine Study Highlights Need for Rapid, PCR-based Group B Streptococcus (GBS) Testing at Time of Admission for Labor and Delivery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 Date: Friday, April 11, 2014 ... Country Club, 1360 Almshouse Road, Warrington, Pa. , ... solely dedicated to finding a cure for hepatitis B and ... host its annual Crystal Ball on Friday, April 11 at ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging ... to serve the wound care market. , Free report ... was restructured with a seasoned management team and Board, ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors ... Plague.” In this time period, doctors did not know that ... to the death of vulnerable patients. In the same way, ... may be unwittingly transmitting herpes viruses to their patients. The ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... BOSTON, Mass., June 4 Experts with ... PAREXEL,International Corporation (Nasdaq: PRXL ), a ... 2008 BIO,International Convention to be held June ... in San Diego, California. PAREXEL has worked ...
... do the French get away with a clean bill of ... The answer to the so-called "French paradox" may be found ... doses of resveratrol, a natural constituent of grapes, pomegranates, red ... an international team of researchers. , Writing this week (June ...
... Mass., June 3 Xceed Molecular, a ... analysis,systems, has granted Gen-Probe Incorporated (Nasdaq: ... to use Xceed,s novel Flow-Thru Chip,technology. Gen-Probe ... its,next-generation multiplexed molecular-diagnostics products. Gen-Probe is a,global ...
Cached Biology Technology:PAREXEL Product Development and Regulatory Experts to Attend the 2008 BIO International Convention 2PAREXEL Product Development and Regulatory Experts to Attend the 2008 BIO International Convention 3PAREXEL Product Development and Regulatory Experts to Attend the 2008 BIO International Convention 4Agent in red wine found to keep hearts young 2Agent in red wine found to keep hearts young 3Xceed Molecular Grants Gen-Probe License to Xceed's Flow-Thru Chip(R) Technology for Multiplex Molecular Diagnostics 2
(Date:4/24/2014)... WEST LAFAYETTE, Ind. - Purdue and West Virginia University ... the golden eagle, providing a bird,s-eye view of eagle ... , Their study calls into question long-held assumptions ... not be as sensitive to ultraviolet light as previously ... have a sharper sense of smell than researchers realized. ...
(Date:4/24/2014)... published in the Scientific Reports journal. , CSIC ... joint centre of CSIC and Pompeu Fabra University-UPF), explains: "When ... we saw that it did not match with the DNA ... the complete genome and to make a functional interpretation in ... Louis XVI". , The functional genome analysis was based ...
(Date:4/24/2014)... N.C. -- A new study representing the largest study of ... broader diets have better self-control. , Published this week in ... , the study is part of a long history of ... some species able to do things like make and use ... others aren,t? , Until now, most studies of animal ...
Breaking Biology News(10 mins):Genome yields insights into golden eagle vision, smell 2The blood preserved in the pumpkin did not belong to Louis XVI 2Animals with bigger brains, broader diets have better self control 2Animals with bigger brains, broader diets have better self control 3
... detection techniques developed at the University, the team mapped ... and developed a model of their likely distribution as ... action is needed. University of Canberra professor in ... found foxes are widespread in northern and eastern Tasmania ...
... University of Southampton has shown that copper can ... to the increasing number of antibiotic-resistant infections worldwide. ... largely responsible for the development of antibiotic-resistance, which ... healthcare-associated infections (HCAIs). The newly-published paper, which ...
... Institution are rolling out results from the new Airborne ... at the American Geophysical Union (AGU) meetings in San ... uncovering a previously invisible ecological world. To watch a ... the world in a whole new way, click here. ...
Cached Biology News:Fox invasion threatens wave of extinction, UC research finds 2New study shows how copper restricts the spread of global antibiotic-resistant infections 2Carnegie debuts revolutionary biosphere mapping capability at AGU 2Carnegie debuts revolutionary biosphere mapping capability at AGU 3
Porcine Serum Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Potassium Oxalate N-10: EDTA (Na) N-03: Alsevers N-05: ACD N-07: CPD N-09: K3EDTA N-11...
Recombinant Viral CCI/Fc Chimera, CF...
... • Guinea Pig serum is collected from fasted ... N-02: Citrate N-04: Heparin (Na) ... Oxalate N-10: EDTA (Na) N-03: ... CPD N-09: K3EDTA N-11: ...
GENOMIPHI V2 DNA AMP KIT 25RXN, 1 EA. Category: Genomics DNA Amplification....
Biology Products: